Linezolid
- Generic Name
- Linezolid
- Brand Names
- Zyvox, Zyvoxam
- Drug Type
- Small Molecule
- Chemical Formula
- C16H20FN3O4
- CAS Number
- 165800-03-3
- Unique Ingredient Identifier
- ISQ9I6J12J
- Background
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...
- Indication
Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...
- Associated Conditions
- Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection
- Associated Therapies
- -
A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.
- Conditions
- Interventions
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01039610
Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT00990990
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Conditions
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2010-03-18
- Lead Sponsor
- Novexel Inc
- Target Recruit Count
- 180
- Registration Number
- NCT00949130
- Locations
- 🇺🇸
Fountain Valley Regional Hospital and Medical Center, Fountain Valley, California, United States
🇺🇸Idaho Falls Infectious Diseases, Idaho Falls, Idaho, United States
🇺🇸Mercury Street Medical Group, Butte, Montana, United States
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Arrevus Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00948142
Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Aarhus University Hospital
- Registration Number
- NCT00925093
Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
- Conditions
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Registration Number
- NCT00876850
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 143
- Registration Number
- NCT00865280
- Locations
- 🇺🇸
Paratek Recruiting Site, Savannah, Georgia, United States
🇺🇸Parateck Recruiting Site, Columbus, Georgia, United States
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
- Conditions
- Interventions
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Stiefel, a GSK Company
- Target Recruit Count
- 410
- Registration Number
- NCT00852540
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
- Conditions
- Interventions
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 150
- Registration Number
- NCT00711854
- Locations
- 🇨🇭
Geneva University Hospitals, Geneva, Switzerland
Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 26
- Registration Number
- NCT00691392
- Locations
- 🇿🇦
King George V Hospital, Durban, KwaZulu Natal, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.